Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01390870|
Recruitment Status : Completed
First Posted : July 11, 2011
Results First Posted : March 21, 2012
Last Update Posted : May 17, 2017
|Condition or disease||Intervention/treatment|
|Prostatic Hyperplasia||Drug: 5ARI or AB or Combination Therapy (5ARI + AB)|
|Study Type :||Observational|
|Actual Enrollment :||400 participants|
|Official Title:||Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence|
|Study Start Date :||May 2009|
|Primary Completion Date :||September 2010|
|Study Completion Date :||September 2010|
Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
Drug: 5ARI or AB or Combination Therapy (5ARI + AB)
5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
- Number of Participants Reporting Compliance With Medication [ Time Frame: Cross sectional survey administered once to each participant during a 17-month study period (May 2009 to September 2010) ]Compliance was calculated based on the participant's response to the following question: "In general, how many times did you miss taking your prostate medication?" Responses were measured on a 5-point scale. Participants who answered "I never miss a dose of my medication" were considered compliant. All other responses were considered non-compliant.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01390870
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|